OLIGOMERIX Funded by the Alzheimer's Drug Discovery Foundation to Evaluate Compounds Active Against Tau Oligomers, a Novel Target for Therapeutic Development
Published: Jul 07, 2008
NEW YORK, NY--(Marketwire - July 07, 2008) - OLIGOMERIX, Inc. today announced receipt of a program related investment of $100K from the Alzheimer's Drug Discovery Foundation (ADDF). The focus of the program is to select compounds using its proprietary Alzheimer's disease (AD) screening assays active against tau oligomers, and to evaluate these compounds in a tauopathy mouse model. The work will be done in collaboration with Dr. Ottavio Arancio, MD, PhD (Columbia University Medical Center) and Dr. Donald Weaver, MD, PhD (Dalhousie University), both of whom are co-principal investigators.